Trends in Formulation for Highly Potent Drugs
By Jill Murphy
Feature
Article
Pharmaceutical TechnologyTrends in Formulation, October 2023 eBook
Volume 2023 eBook
Issue 5
Pages: 12-14
When considering manufacturing and the growth of drug formulation, it is evident that there has been change and many new advancements introduced to make processes more efficient.
H_Ko - Stock.adobe.com
When considering manufacturing and the growth of drug formulation, it is evident that there has been change and many new advancements introduced to make processes more efficient. However, in terms of formulating highly potent drugs, their specific release requirements and poor aqueous bioavailability make them challenging to produce and analyze (1).
Although there may be difficulties seen with analytical challenges, the strength of oral solid dosage (OSD) forms and the manufacture of all pharmaceutical finished dosage forms continues to be prominent. According to research, the OSD market outlook is expected to continue growing and have low production costs, even with the knowledge of how unpredictable formulation may become (2).
Pharmaceutical Technology® discussed new formulation trends with Shailesh Vengurlekar, senior VP of Quailty and Regulatory Affairs at LGM Pharma, and how the industry can go forward with these advancements, despite any challenges that may arise.
Read this article in the Trends in Formulation 2023 eBook
About the author
Jill Murphy is Editor at Pharmaceutical Technology.
Article details
Pharmaceutical Technology
eBook: Trends in Formulation
October 2023
Pages: 12-14
Citation
When referring to this article, please cite it as J. Murphy, "Trends in Formulation for Highly Potent Drugs," Pharmaceutical Technology's Trends in Formulation eBook (October 2023).
Recent Videos
Related Content
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024Podcast
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Article
Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024Podcast
In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
